| For: | Yang ZY, Zhao YW, Xue JR, Guo R, Zhao Z, Liu HD, Ren ZG, Shi M. Thioridazine reverses trastuzumab resistance in gastric cancer by inhibiting S-phase kinase associated protein 2-mediated aerobic glycolysis. World J Gastroenterol 2023; 29(45): 5974-5987 [PMID: 38130998 DOI: 10.3748/wjg.v29.i45.5974] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v29/i45/5974.htm |
| Number | Citing Articles |
| 1 |
Hui-Hui Hu, Sai-Qi Wang, Huichen Zhao, Zhe-Sheng Chen, Xiaojing Shi, Xiao-Bing Chen. HER2+ advanced gastric cancer: Current state and opportunities (Review). International Journal of Oncology 2024; 64(4) doi: 10.3892/ijo.2024.5624
|
| 2 |
Abdulaziz H. Al Khzem, Mohamed S. Gomaa, Mansour S. Alturki, Nada Tawfeeq, Mohammad Sarafroz, Shareefa M. Alonaizi, Alhassan Al Faran, Laela Ahmed Alrumaihi, Fatimah Ahmed Alansari, Abdullah Abbas Alghamdi. Drug Repurposing for Cancer Treatment: A Comprehensive Review. International Journal of Molecular Sciences 2024; 25(22): 12441 doi: 10.3390/ijms252212441
|
| 3 |
Zexing Shan, Yefu Liu. Harnessing glycolysis in gastric cancer: molecular targets, therapeutic strategies, and clinical horizons. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1628937
|
| 4 |
Alba Valero-Almingol, Sheyla Montori, Nayra Felípez, Enrique Santamaría, Joaquín Fernandez-Irigoyen, Irina Luzko, Anabella A Cuestas, Carlos Pardo, Ricard Prat, Leticia Moreira, Eduardo Albéniz. Targetable pathways for drug repurposing in gastric cancer. World Journal of Gastroenterology 2025; 31(39): 110986 doi: 10.3748/wjg.v31.i39.110986
|
